stocks logo

AMRX

Amneal Pharmaceuticals Inc
$
8.090
-0.08(-0.979%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.215
Open
8.170
VWAP
--
Vol
1.54M
Mkt Cap
2.54B
Low
8.070
Amount
--
EV/EBITDA(TTM)
8.72
Total Shares
308.65M
EV
5.08B
EV/OCF(TTM)
16.57
P/S(TTM)
0.90
Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
744.56M
+6.1%
0.175
+9.31%
779.66M
+10.99%
0.175
+9.25%
791.74M
+8.38%
0.154
+28.2%
Estimates Revision
The market is revising Downward the revenue expectations for Amneal Pharmaceuticals, Inc. (AMRX) for FY2025, with the revenue forecasts being adjusted by -0.35% over the past three months. During the same period, the stock price has changed by 5.61%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.95%
In Past 3 Month
Stock Price
Go Up
up Image
+5.61%
In Past 3 Month
3 Analyst Rating
up Image
42.15% Upside
Wall Street analysts forecast AMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMRX is 11.50 USD with a low forecast of 11.00 USD and a high forecast of 12.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
up Image
42.15% Upside
Current: 8.090
sliders
Low
11.00
Averages
11.50
High
12.00
Goldman Sachs
Matt Dellatorre
Buy
initiated
$12
2025-06-06
Reason
Goldman Sachs analyst Matt Dellatorre initiated coverage of Amneal Pharmaceuticals with a Buy rating and $12 price target. The firm expects continued momentum across the portfolio and sees upside to consensus estimates. Goldman sees Amneal's generics segment remaining the key component and driver of EBITDA growth, driven by the company's strong product pipeline, including biosimilar and sterile injectable launches.
Barclays
Balaji Prasad
Buy
Maintains
$10 → $11
2025-03-03
Reason
JP Morgan
Chris Schott
Hold
to
Buy
Upgrades
$9 → $12
2025-02-24
Reason
Piper Sandler
David Amsellem
Buy
Maintains
$9 → $11
2024-11-11
Reason
Piper Sandler raised the firm's price target on Amneal Pharmaceuticals to $11 from $9 and keeps an Overweight rating on the shares. The firm notes Amneal reported Q3 adjusted diluted EPS of 16c on revenue of $702M, compared to Street estimates of 13c and $694M, respectively. The company reiterated 2024 total revenue and adjusted EBITDA guidance ranges of $2.7B-$2.8B and $610M-$630M, respectively.
Truist Securities
Les Sulewski
Strong Buy
Maintains
$10 → $12
2024-10-02
Reason
Truist analyst Les Sulewski raised the firm's price target on Amneal Pharmaceuticals to $12 from $10 and keeps a Buy rating on the shares. The firm has followed up with the company's management post Metsera collaboration news to gain insight into the agreement and entrance into the GLP1 space as a supplier for U.S./E.U. markets and commercial leadership ex-U.S., the analyst tells investors in a research note. Despite Metsera's early stage foray into next-gen GLP1s, the partnership solidifies Amneal as a commercial partner with scale, opening the door for additional GLP1 manufacturing contracts, the firm states, adding that its $200M investment in a new India facility will leverage Amneal's complex manufacturing knowhow and boost its peptide footprint to drive additional partnerships.
JP Morgan
Chris Schott
Sell
to
Hold
Upgrades
$9
2024-09-06
Reason

Valuation Metrics

The current forward P/E ratio for Amneal Pharmaceuticals Inc (AMRX.N) is 12.13, compared to its 5-year average forward P/E of 7.45. For a more detailed relative valuation and DCF analysis to assess Amneal Pharmaceuticals Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PE
7.45
Current PE
12.13
Overvalued PE
10.55
Undervalued PE
4.36

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
6.73
Current EV/EBITDA
7.65
Overvalued EV/EBITDA
7.69
Undervalued EV/EBITDA
5.76

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Overvalued
5Y Average PS
0.44
Current PS
0.83
Overvalued PS
0.71
Undervalued PS
0.17

Financials

Annual
Quarterly
FY2025Q1
YoY :
+5.50%
695.42M
Total Revenue
FY2025Q1
YoY :
+12.46%
95.80M
Operating Profit
FY2025Q1
YoY :
-130.14%
24.62M
Net Income after Tax
FY2025Q1
YoY :
-113.33%
0.04
EPS - Diluted
FY2025Q1
YoY :
-54.84%
-10.91M
Free Cash Flow
FY2025Q1
YoY :
+1.91%
36.80
Gross Profit Margin - %
FY2025Q1
YoY :
+65.66%
8.25
FCF Margin - %
FY2025Q1
YoY :
-128.57%
3.54
Net Margin - %
FY2025Q1
N/A
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.0M
USD
6
3-6
Months
46.6M
USD
8
6-9
Months
1.9M
USD
7
0-12
Months
491.4K
USD
2
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
1
14.2K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

AMRX News & Events

Events Timeline

2025-07-21 (ET)
2025-07-21
07:42:11
Amneal Pharmaceuticals announces proposed refinancing of credit agreement
select
2025-07-21
07:40:51
Amneal Pharmaceuticals sees Q2 revenue $720M-$730M, consensus $753.34M
select
2025-07-18 (ET)
2025-07-18
07:03:49
Knight Therapeutics announces CREXONT NDS accepted for Health Canada review
select
Sign Up For More Events

News

3.0
07-29NASDAQ.COM
Amneal (AMRX) is an Incredible Growth Stock: 3 Reasons Why
8.5
07-21Newsfilter
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
9.5
07-21Newsfilter
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
Sign Up For More News

FAQ

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX) stock price today?

The current price of AMRX is 8.09 USD — it has decreased -0.98 % in the last trading day.

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX)'s business?

arrow icon

What is the price predicton of AMRX Stock?

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX)'s revenue for the last quarter?

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Amneal Pharmaceuticals Inc (AMRX)'s fundamentals?

arrow icon

How many employees does Amneal Pharmaceuticals Inc (AMRX). have?

arrow icon

What is Amneal Pharmaceuticals Inc (AMRX) market cap?